Research programme: allergic rhinitis vaccine - AFFiRiS

Drug Profile

Research programme: allergic rhinitis vaccine - AFFiRiS

Latest Information Update: 19 Jan 2016

Price : $50

At a glance

  • Originator AFFiRiS
  • Class Allergy immunotherapies; Antiallergics; Peptide vaccines
  • Mechanism of Action Immunoglobulin E modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Allergic rhinitis

Most Recent Events

  • 18 Jan 2016 Preclinical trials in Allergic rhinitis in Austria (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top